4th Quarter - Report

HARMONY BIOSCIENCES for HARMONY BIOSCIENCES

Period 4th Quarter 2024 Filed Jan 17, 2025 Signed by Cate McCanless

Official filing
Firm
HARMONY BIOSCIENCES
Client
HARMONY BIOSCIENCES
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

H.R. 5547, Maintaining Investments in New Innovation (MINI) Act H.R.7174, Ensuring Pathways to Innovative Cures (EPIC) Act H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act H.R. 6664, Innovation in Pediatric Drugs Act H.R. 7384, Creating Hope Reauthorization Act H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act H.R.7024, Tax Relief for American Families and Workers Act of 2024 H.R.3433 / S.2897, Give Kids a Chance Act

LobbyistCovered position, as disclosed
SUSANNA AGUIRRE HASTINGS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3433 (118th), H.R. 6664 (118th), H.R. 7024 (118th), H.R. 5547 (118th), H.R. 7383 (118th), H.R. 7174 (118th), S. 2897 (118th), H.R. 6094 (118th), H.R. 7384 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.